SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Leukosite (LKST)promising new biotech Cy?
LKST 4.2600.0%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Pseudo Biologist who wrote (25)3/30/1999 11:26:00 PM
From: ACC  Read Replies (1) of 35
 
Thanks for the info -

I'm no hematologist but I think NHL is more responsive
to current chemotherapy than CLL. CLL tends to be more common
among older patients, who may also have a worse prognosis, so more effort is concentrated on CLL, but NHL ought definitely to be an
indication if clinical studies of Campath-1H show good results
in CLL treatment.

ACC
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News